EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy

Yuan Ma, Huarui Zhang, Xinyang Shen, Xin Yang, Yan Deng, Yuan Tian, Zefeng Chen, Yufei Pan, Hang Luo, Chuanxin Zhong, Sifan Yu, Aiping Lu und 3 weitere

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Yuan Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Law Sau Fai Institute for Advancing Translational Medicine in Bone &Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Ko…. Hauptthemen laut MEDLINE: Tumor Hypoxia, Hypoxia-Inducible Factor 1, alpha Subunit, Breast Neoplasms, Aptamers, Nucleotide. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, University Grants Committee, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer. Hypoxia-activated prodrugs (HAPs) have shown promise as potential therapeutic agents for TNBC. While increasing hypoxia levels may promote the HAP activation, it raises concerns regarding HIF1α-dependent drug resistance. It is desirable to develop a targeted approach that enhances tumor hypoxia for HAP activation without promoting HIF1α-dependent drug resistance in TNBC treatment. Herein, we proposed a multi-responsive carrier-free self-assembled nanomedicine named AQ4N@CA4T1ASO. This nanomedicine first targeted tumors by the TNBC-targeting aptamers (T1), and then disassembled in the reductive and acidic conditions within tumors. The released Combretastatin 4 (CA4) could exacerbate hypoxia, thereby promoting the conversion of inactive Banoxantrone (AQ4N) to its active form, AQ4. Simultaneously, the released antisense oligonucleotide (ASO) could attenuate hypoxia-induced HIF1α mRNA expression, thereby sensitizing the tumor to chemotherapy. Overall, this smart nanomedicine represents a profound targeted therapy strategy, combining "hypoxia-potentiating, hypoxia-activated, chemo-sensitization" approaches for TNBC treatment. In vivo study demonstrated significant suppression of tumor growth, highlighting the promising potential of this nanomedicine for future clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor HypoxiaHypoxia-Inducible Factor 1, alpha SubunitBreast NeoplasmsAptamers, NucleotideHumansCell Line, TumorGene Expression Regulation, NeoplasticBibenzylsOligonucleotides, AntisenseProdrugsNanomedicineCell ProliferationCell CycleApoptosisFemaleAnimalsMiceMice, Inbred BALB CXenograft Model Antitumor Assays

Stichwörter der Autor:innen

AptamerHypoxia-activated prodrugHypoxia-inducible factorHypoxia-potentiating agentTriple-negative breast cancer

Substanzen

HIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitcombretastatinBibenzylsOligonucleotides, AntisenseProdrugsAptamers, Nucleotide

Autor:innen und Institutionen

  • Law Sau Fai Institute for Advancing Translational Medicine in Bone &Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, 999077, China.
  • Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China.
  • Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
  • Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China. Electronic address: tangtao@cuhk.edu.hk.
  • Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China; Department of Gynecology, The Sixth Affiliated Hospital of Jinan University, Dongguan Eastern Central Hospital, Dongguan, Guangdong…
  • Law Sau Fai Institute for Advancing Translational Medicine in Bone &Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, 999077, China. Electronic address: zhangge@hkbu.edu.hk.

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • University Grants Committee
  • National Key Research and Development Program of China
  • Excellent Young Scientists Fund
  • Ministry of Science and Technology of the People's Republic of China
  • Department of Science and Technology of Hunan Province
  • Innovation and Technology Commission
  • Shenzhen Science and Technology Innovation Committee

Zitieren

APA

Ma, Y., Zhang, H., Shen, X., Yang, X., Deng, Y., Tian, Y., Chen, Z., Pan, Y., Luo, H., Zhong, C., Yu, S., Lu, A., Zhang, B., Tang, T., & Zhang, G. (2024). Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217102

Vancouver

Ma Y, Zhang H, Shen X, Yang X, Deng Y, Tian Y, et al. Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217102

BibTeX
@article{Ma2024,
  author = {Ma, Yuan and Zhang, Huarui and Shen, Xinyang and Yang, Xin and Deng, Yan and Tian, Yuan and Chen, Zefeng and Pan, Yufei and Luo, Hang and Zhong, Chuanxin and Yu, Sifan and Lu, Aiping and Zhang, Baoting and Tang, Tao and Zhang, Ge},
  title = {Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217102}
}
Kostenlos starten →